Canaccord analyst William Plovanic lowered the firm’s price target on TransMedics (TMDX) to $124 from $152 and keeps a Buy rating on the shares. The firm said they released a mixed quarter with total revenue and adjusted EPS falling short of expectations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics Group: Buy Rating Reiterated as Transplant Volumes Support Growth; $190 Price Target Maintained
- TransMedics signs agreement to invest in PAD Aviation
- TransMedics Maintained at Buy as CHOPS Platform Broadens Transplant Offering; $152 Price Target Reiterated
- TransMedics: Strengthening Leadership in Organ Preservation Through Rigorous Clinical Trials and Normothermic Perfusion Evidence
- William Blair healthcare IT analysts hold analyst/industry conference call